Spending More or Less, and on What? - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Spending More or Less, and on What?
Pharmaceutical Technology's annual survey on equipment and machinery reveals the spending levels and types of spending made in 2009 and planned for 2010.

Pharmaceutical Technology
Volume 34, Issue 4, pp. 48-56

Areas of spend

Figure 1:
So in what areas did companies spend the most in 2009? Thirty-one percent of respondents spent the most on solid-dosage manufacturing. Parenteral manufacturing or sterile manufacturing/aseptic processing ranked as the second highest area with 18.5% spending the most in this area, and 15.8% spent the most on biologic-based API manufacturing (see Figure 1).

Figure 2:
A similar pattern exists for planned spending in 2010. Respondents plan to spend the most in solid-dosage manufacturing (28% of respondents). Almost 20% of respondents (19.1%) plan to spend the most in parenteral manufacturing or aseptic processing/sterile manufacturing, and 16.6% will spend the most in biologic-based API manufacturing (see Figure 2).

Impact factors

Figure 3:
The survey also examined the factors that influenced purchasing decisions. As might be expected, compliance with good manufacturing practices (GMPs) was a leading reason behind spending decisions. The survey showed that 56.1% of respondents said compliance with GMPs was a "high-impact" factor in their purchasing decisions, and 26.5% said it had "medium impact" (see Figure 3). Macroeconomic conditions also had a large effect. The survey showed that 41.4% of respondents said overall economic conditions had a "high impact" on their purchasing decisions (See Figure 3). Other high-impact factors were expansion of manufacturing facilities (35.6% of respondents cited as a high-impact factor), replacement of existing equipment (22.3%), and upgrades or addition of technology (24.2%). Interestedly, initiatives such as QbD and PAT seemed to have little impact on purchasing decisions. Two-thirds of respondents said that PAT had "little or no impact" on their purchasing decisions, and 51.9% said QbD had "little or no impact" on their spending decision in 2009.

Figure 4:
A similar pattern emerges for 2010. As in 2009, GMP compliance was the leading reason for purchasing machinery and equipment in 2010, with 75.5% of respondents citing GMP compliance as a "high- or medium- impact" factor (see Figure 4). As overall economic conditions improve somewhat in 2010, the economy, although still a crucial factor, is not negatively affecting purchasing decisions as much in 2010 as it did in 2009. The survey showed that 68.7% of respondents said that overall economic conditions are a "high- or medium- impact factor" on their spending plans for 2010 compared with 77.5% that ranked the economy as a "high- or medium-impact" factor in 2009 (see Figure 4). As in 2009, the influence of PAT and QbD is having a minimal effect on 2010 purchasing decisions. (see Figure 4).


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Source: Pharmaceutical Technology,
Click here